Telemark Asset Management’s Moderna MRNA Stock Holding History

Telemark Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49M	Buy	700,000 +200,000	+40%	+$10.3M	3.54%	5
2026 Q1	$25.4M	Buy	+500,000	New	+$23.3M	2.35%	13
2025 Q4	–	Sell	-500,000	Closed	-$12.9M	–	59
2025 Q3	$12.9M	Buy	+500,000	New	+$13.9M	1.23%	28
2024 Q3	–	Sell	-250,000	Closed	-$29.7M	–	66
2024 Q2	$29.7M	Hold	250,000	–	–	2.58%	8
2024 Q1	$26.6M	Buy	+250,000	New	+$25.2M	2.75%	7
2023 Q4	–	Sell	-200,000	Closed	-$20.7M	–	56
2023 Q3	$20.7M	Hold	200,000	–	–	3.13%	10
2023 Q2	$24.3M	Buy	200,000 +50,000	+33%	+$6.67M	3.3%	13
2023 Q1	$23M	Sell	150,000 -150,000	-50%	-$24.7M	3.42%	14
2022 Q4	$53.9M	Buy	300,000 +50,000	+20%	+$8.18M	8.17%	1
2022 Q3	$29.6M	Buy	250,000 +60,000	+32%	+$9.1M	4.64%	7
2022 Q2	$27.1M	Sell	190,000 -10,000	-5%	-$1.43M	4.59%	5
2022 Q1	$34.5M	Sell	200,000 -50,000	-20%	-$8.42M	3.04%	7
2021 Q4	$63.5M	Sell	250,000 -100,000	-29%	-$29.2M	4.54%	4
2021 Q3	$135M	Buy	350,000 +50,000	+17%	+$18.4M	9.75%	1
2021 Q2	$70.5M	Buy	300,000 +65,000	+28%	+$11.6M	5.63%	2
2021 Q1	$30.8M	Buy	+235,000	New	+$34.1M	2.61%	9

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Telemark Asset Management's MRNA Position: Q2 2026 in Review

Telemark Asset Management increased its Moderna (MRNA) stake by 40% in Q2 2026, buying an estimated $10.3M and bringing the position to 700,000 shares worth $49M. The position accounts for 3.54% of the portfolio, ranked #5.

Telemark Asset Management first reported a position in MRNA in Q1 2021 and has held it in 16 quarters since. The position peaked at $135M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Telemark Asset Management held 700,000 shares of Moderna worth $49M as of Q2 2026.
Telemark Asset Management bought 200,000 Moderna shares in Q2 2026, an estimated $10.3M.
Moderna made up 3.54% of Telemark Asset Management's portfolio in Q2 2026, its #5 holding.
Telemark Asset Management first reported a position in Moderna in Q1 2021 and has held it in 16 quarters since.
Telemark Asset Management's Moderna position peaked at $135M in Q3 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Telemark Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.